Novel IO Approaches Demonstrate High pCR Rates in the Neoadjuvant Setting, Questioning the Need for Surgery in Certain Patients With CRC

Despite recent advances in immunotherapy, certain subtypes of colorectal cancer, such as those that are MSI-high, dMMR of TMB-H, remain a treatment challenge. Moreover, the optimal therapeutic approach for colorectal cancer in the neoadjuvant setting remains elusive, with recent data pointing to combination approaches as potentially beneficial.

Read More